Bluebird, Celgene myeloma treatment impresses in tiny study

(Reuters) - Most patients who previously were not helped by repeated treatments for multiple myeloma showed strong benefits from a new type of therapy in a small study, and with no worrisome side effects, drugmaker Bluebird Bio Inc said on Wednesday.